Infusion Nursing Notes Blog | All posts tagged 'Primary-immunodeficiency-diseases'

Hizentra® 20% Prefilled Syringe Administration: Best Practices and Administration Guidelines

28. April 2025 Candy Finley (0)

Hizentra® is indicated for Primary immunodeficiency (PI) in adults and pediatric patients 2 years of age and older and maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy (CIDP). Upon initial FDA approval, Hizentra® was commercially available in vials only. The manufacturer of Hizentra®, CSL Behring, has since transitioned from vials to prefilled syringes (PFS). Hizentra® is available in 1 gm/5 mL, 2 gm/10 mL, 4 gm/20 mL, and 10 gm/50 mL sizes. The recommended Hizentra® dose and volume, rate per SC site and volume per SC site are typically greater in CIDP compared to PI. [More]

Disease States: Primary Immune Deficiency Diseases (PIDDs)

9. September 2022 Jean McCaslin Disease States, Nursing Support (0)

There are greater than 400 forms of Primary Immune Deficiency Diseases (PIDDs) recognized by the International Union of Immunological Societies.1 These rare genetic diseases are chronic, at times debilitating, and often costly per the National Institute of Health (NIH).1 PIDDs are also known as Inborn Errors of Immunity (IEI). These can affect anyone regardless of gender, age, or ethnicity. They share a common thread; part of the immune system is missing or not functioning properly. This leads to the hallmark of increased susceptibility to infection; it could involve the sinuses, lungs, skin, ears, throat, spinal cord, brain, urinary tract or intestinal tracts. Physical exam may also identify signs of a PIDD including enlargement of lymph nodes, the liver or spleen. For some, inflammatory bowel disease, autoimmune symptoms or blood vessel inflammation could indicate a PIDD. [More]

IVIG Clinical Trials: How Can You Participate?

1. October 2013 Elissa Ritt (1)

To assess whether patients with a specific disease will improve with IVIG therapy, scientists conduct clinical trials, or studies. In order to participate, patients must know who to contact. [More]

COVID 19 Pre-Visit Screen • Nursing Visit Guidance

Infusion Nursing Notes by Nufactor provides education, resources and support to promote successful patient therapy within the infusion nursing community.

Hizentra® 20% Prefilled Syringe Administration: Best Practices and Administration Guidelines

Disease States: Primary Immune Deficiency Diseases (PIDDs)

IVIG Clinical Trials: How Can You Participate?

Payers

Support

About Us

Nufactor